PTO/SB/08a (08-03)
Approved for use through 97/31/2006, OMS 0651-0201
U.S. Patient and Trademark Office, U.S. DEPARTMENT OF COMMERCE to a collection of information unfers it contains a valid OMS control number. Under the Paperwork Reduction Act of 1995, no persons are required to

INFORMATION DISCLOSURE STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		10581698	
Filing Date		2005-06-09	
First Named Inventor	TAKA	ASHI KENMOKU ET AL.	
Art Unit		1711	
Examiner Name TERR		RESSA M. BOYKIN	
Attorney Docket Number		03500.103896	

U.S.PATENTS							Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code1 Issue Date Name of Patentee or Applicant of cited Document		Releva	Columns,Lines where ant Passages or Relev s Appear				
	1	4265247	A	1981-05	-05	Lenz et al.				
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	per Code1 Date Name of Patentee or Applicant		Releva	Columns,Lines where ant Passages or Relev s Appear				
	1	20070155912	A1	2007-07	-05	Kenmoku et al	L			
	2	20060247414	A1	2006-11	-02	Kenmoku et al	L			
	3	20070117937	A1	2007-05	-25	Kenmoku et al	L			
If you wis	h to a	dd additional U.S. Publi	shed Ap	plication	citation	n information p	olease click the Ad	d buttor	Add	
				FOREIG	SN PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	Ts
	1	2-3415	JP		A	1990-01-09	NIPPON SHOJI KA	,		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10581698		
Filing Date		2005-06-09		
First Named Inventor TAKA		ISHI KENMOKU ET AL.		
Art Unit		1711		
Examiner Name TERR		RESSA M. BOYKIN		
Attorney Docket Number		03500.103896		

	2	59-190945	JP	A	1984-10-29	JAPAN SYNTHETIC RUBBER CO. LTD.		
	3	2005/121204	wo	A2	2005-12-22	CANON KK		
If you wis	h to a	dd additional Foreign P	atent Document	citation	information pl	lease click the Add button	Add	
			NON-PATER	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Cite No		nal, serial, symp	osium,	catalog, etc), o	the article (when appropr date, pages(s), volume-is		Ţ5
	1	Miliani Trollisis et al., "Hydrophilic Alighatic Polyesters: Design, Synthesis, and Ring-Opening Polymerization of Functional Cyclo Esters," 33 Micromot. 4819-27 (2000).						
	2	S. Ponsart et al., "A Novel Route to Polyti-caprolactone)-Based Copolymers via Antonio Derivatization," 1 Biomolecules 275-81 (2000).						
	3 Benjamin Saurirer et al., "Lactic Acrid-Based Functionalized Polymers via Copolymerzation and Chemical Modification." 4 Macromol. Biosci. 232-37 (2004).							
	4	Bryan Pierrich et al., "Functional Polyesters by Ring-Opening Polymerization of a-ally(5-valerolactorie)," 87 Polymer. [
	5	C.P. Radiano et al., "Synthesis of Novel Biodegraduble Copolyesters Using Olefin Metathesis," 43(2) Polymer Reprints [727-28 (2002).						
	6	Telsuji Yarnaoka et al., "Synthesis and Properties of Malic Acid-Containing Functional Polymers," 25 Intl. J. Biol. Macromol. 265-71 (1999).						
	7	Lindsay H. Briggs et al., "Degradation of the Lancellerol Side-Chain," J.C.S. Perkin I, 806-09 (1973).						

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10581698		
Filing Date		2005-06-09		
First Named Inventor	TAKA	SHI KENMOKU ET AL.		
Art Unit		1711		
Examiner Name TERF		ESSA M. BOYKIN		
Attorney Docket Number		03500.103896		

	8	Organ	nic Synthesis, vol. 4, pp. 698-99 (1963).					
	9	Harry (1981	R. Alloock et al., "Reactions of Steroid Salts with Hexachiorocycle).	otriphosphazene,* 46	J. Org. Chem. 13-22			
	J.K. Sille et al., "Tehacyclic Dienes. I. The Diels-Alder Addruct of Nortromadiene and Cyclopertadiene," 81 J. Am. Chem. Soc. 4273-75 (August 1959).							
Maris-Mauf Bear et al., "Preparation of a Bacterial Polyester with Carbony Groups in Side Chars," 4 Chemistry 289-93 (2001).								
	12 Gary A. Molander et al., "Sequenced Reactions with Samarium(II) lodide. Tandem Inframolecular Nucleophilic Acyl Substitution/inframolecular Barbler Cyclications," 117 J. Am. Chem. Soc. 3705-16 (1995).							
If you wis	If you wish to add additional non-patent literature document citation information please click the Add button Add							
	EXAMINER SIGNATURE							
Examiner	Examiner Signature Date Considered							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kint Cote of USPTO Patent Documents at Invent_USPTO_GOLy or MPEP 90.04. Enter of thice that issued the document, by the Involvement of the Standard ST3.) For Suparsees patent for counters, the notice of on the year of the region of the Emperor many precises the sensit number of the patent for the patent of the Standard ST3.) For Suparsees patent for sensitive or the patent for the Standard ST3. The

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10581698
Filing Date		2005-06-09
First Named Inventor TAKA		ISHI KENMOKU ET AL.
Art Unit		1711
Examiner Name TERF		RESSA M. BOYKIN
Attorney Docket Number		03500.103896

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 an	d 1.98 to make the	appropriate selection(s):
---------------	-------------	--------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patient office in a counterpart foreign application not more than three months prior to the filling of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any involved designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Jason M. Okun/	Date (YYYY-MM-DD)	2007-07-06
Name/Print	Jason M. Okun	Registration Number	48512

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file fand by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.